药物发现论文趋势 2023–2026
分子与蛋白设计
统计范围:NeurIPS、ICLR、ICML、CVPR 四个会议,2023–2026 年,共 578 篇被归入该主题的论文。
主要结论
- 药物发现论文从 2023 年的 79 篇增长到 2026 年的 211 篇,三年间扩大到约 2.7 倍。
- NeurIPS 是发药物发现论文最多的会议,2023–2026 年共 234 篇,占四个会议总量的 40%。
- 交叉方向里涨得最快的是应用 · chemistry physics and earth sciences:同时属于两个主题的论文从 2023 年的 1 篇增至 2026 年的 42 篇。
- 在「健康与生命科学」的 5 个主题里,它的 2026 年论文数排第 2;同组增长最快的临床 NLP是 3.2 倍,药物发现是 2.7 倍。
各会议论文数
按年份和会议统计
| 年份 | NeurIPS | ICLR | ICML | CVPR | 合计 |
|---|---|---|---|---|---|
| 2023 | 21 | 22 | 20 | 16 | 79 |
| 2024 | 49 | 23 | 42 | 11 | 125 |
| 2025 | 64 | 48 | 39 | 12 | 163 |
| 2026 | 100 | 37 | 63 | 11 | 211 |
代表论文
按年份和会议均匀挑选,方便快速看到每一届的样貌
- NeurIPS 2026ACER: Towards Generalizable Protein-ligand Co-folding
- ICML 2026Adaptive Symmetry Discovery for Dynamical System Identification
- ICLR 2026Bures Generalized Category Discovery
- CVPR 2026Learning Like Humans Analogical Concept Learning for Generalized Category Discovery
- NeurIPS 2025AANet: Virtual Screening under Structural Uncertainty via Alignment and Aggregation
- ICML 2025Explicit Discovery of Nonlinear Symmetries from Dynamic Data
- ICLR 2025CBGBench: Fill in the Blank of Protein-Molecule Complex Binding Graph
- CVPR 2025Adaptive Part Learning for Fine-Grained Generalized Category Discovery: A Plug-and-Play Enhancement
- NeurIPS 2024A SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models
- ICML 2024Amortized Equation Discovery in Hybrid Dynamical Systems
- ICLR 2024Self-supervised Pocket Pretraining via Protein Fragment-Surroundings Alignment
- CVPR 2024Federated Generalized Category Discovery
- NeurIPS 2023An Optimization-based Approach To Node Role Discovery in Networks: Approximating Equitable Partitions
- ICML 2023A Group Symmetric Stochastic Differential Equation Model for Molecule Multi-modal Pretraining
- ICLR 2023Context-enriched molecule representations improve few-shot drug discovery
- CVPR 2023Bootstrap Your Own Prior: Towards Distribution-Agnostic Novel Class Discovery
- NeurIPS 2026Active Flow Expansion for Out-of-Distribution Discovery: from Theory to Molecules
- ICML 2026CURE: Consistency-under-Unified Semantic Regularization for Generalized Category Discovery
- ICLR 2026Exploring Synthesizable Chemical Space with Iterative Pathway Refinements
- CVPR 2026TAR Token-Aware Refinement for Fine-grained Generalized Category Discovery
全部药物发现论文
共 211 篇,第 1 / 5 页
- CVPR 2026A Polynomial Chaos Framework for Causal Discovery in Nonlinear Uncertain
- CVPR 2026Beyond the Static World Continual Category Discovery under Visual Drift
- CVPR 2026Decouple Your Discovery and Memory in Continual Generalized Category Discovery
- CVPR 2026Differences That Matter Auditing Models for Capability Gap Discovery and
- CVPR 2026Geometric-Aware Hypergraph Reasoning for Novel Class Discovery in Point Cloud
- CVPR 2026H-Sets Hessian-Guided Discovery of Set-Level Feature Interactions in Image Classifiers
- CVPR 2026Learning Like Humans Analogical Concept Learning for Generalized Category Discovery
- CVPR 2026Seeing Through the Shift Causality-Inspired Robust Generalized Category Discovery
- CVPR 2026TAR Token-Aware Refinement for Fine-grained Generalized Category Discovery
- CVPR 2026TRIDENT A Trimodal Cascade Generative Framework for Drug and RNA-Conditioned
- CVPR 2026Unsupervised Monocular 3D Keypoint Discovery from Multi-View Diffusion Priors
- ICLR 2026A Hierarchical Circuit Symbolic Discovery Framework for Efficient Logic Optimization
- ICLR 2026Adaptive Gaussian Expansion for On-the-fly Category Discovery
- ICLR 2026Bures Generalized Category Discovery
- ICLR 2026CAPSUL: A Comprehensive Human Protein Benchmark for Subcellular Localization
- ICLR 2026Causal Discovery in the Wild: A Voting-Theoretic Ensemble Approach
- ICLR 2026Causal Discovery via Quantile Partial Effect
- ICLR 2026ConfHit: Conformal Generative Design via Nested Testing
- ICLR 2026Differentially Private Domain Discovery
- ICLR 2026Disentangled representation learning through unsupervised symmetry group discovery
- ICLR 2026Drugging the Undruggable: Benchmarking and Modeling Fragment-Based Screening
- ICLR 2026DrugTrail: Explainable Drug Discovery via Structured Reasoning and Druggability‑Tailored Preference Optimization
- ICLR 2026Exploring Synthesizable Chemical Space with Iterative Pathway Refinements
- ICLR 2026Flow Expansion via Verifier-Constrained Noised State Space Exploration
- ICLR 2026Formal Mechanistic Interpretability: Automated Circuit Discovery with Provable Guarantees
- ICLR 2026FragFM: Hierarchical Framework for Efficient Molecule Generation via Fragment-Level Discrete Flow Matching
- ICLR 2026From Concepts to Components: Concept-Agnostic Attention Module Discovery in Transformers
- ICLR 2026GEPA: Reflective Prompt Evolution Can Outperform Reinforcement Learning
- ICLR 2026GRAM-DTI: Adaptive Multimodal Representation Learning for Drug–Target Interaction Prediction
- ICLR 2026Hedonic Neurons: A Mechanistic Mapping of Latent Coalitions in Transformer MLPs
- ICLR 2026Influence without Confounding: Causal Discovery from Temporal Data with Long-term Carry-over Effects
- ICLR 2026Interpolation-Based Conditioning of Flow Matching Models for Bioisosteric Ligand Design
- ICLR 2026KGOT: Unified Knowledge Graph and Optimal Transport Pseudo-Labeling for Molecule-Protein Interaction Prediction
- ICLR 2026Multi-Condition Conformal Selection
- ICLR 2026Multi-state Protein Design with DynamicMPNN
- ICLR 2026On Discovering Algorithms for Adversarial Imitation Learning
- ICLR 2026Pallatom-Ligand: an All-Atom Diffusion Model for Designing Ligand-Binding Proteins
- ICLR 2026PepBenchmark: A Standardized Benchmark for Peptide Machine Learning
- ICLR 2026PRISM: Progressive Robust Learning for Open-World Continual Category Discovery
- ICLR 2026RECON: Robust symmetry discovery via Explicit Canonical Orientation Normalization
- ICLR 2026Reference Guided Skill Discovery
- ICLR 2026Refine Drugs, Don’t Complete Them: Uniform-Source Discrete Flows for Fragment-Based Drug Discovery
- ICLR 2026SAIR: Enabling Deep Learning for Protein-Ligand Interactions with a Synthetic Structural Dataset
- ICLR 2026Scaling Multi-Task Bayesian Optimization with Large Language Models
- ICLR 2026ShinkaEvolve: Towards Open-Ended and Sample-Efficient Program Evolution
- ICLR 2026SpectralGCD: Spectral Concept Selection and Cross-modal Representation Learning for Generalized Category Discovery
- ICLR 2026SYNC: Measuring and Advancing Synthesizability in Structure-Based Drug Design
- ICLR 2026Toward Safer Diffusion Language Models: Discovery and Mitigation of Priming Vulnerability
- ICML 2026Adaptive Symmetry Discovery for Dynamical System Identification
- ICML 2026APEX: Approximate-but-exhaustive search for ultra-large combinatorial synthesis libraries
在 Claude、Cursor 里直接问这个趋势
接上 Paperlist MCP 后,写综述、挑方向或准备投稿时,不用离开对话框就能拿到这页的数字:每年各会议的论文数、增长倍数、涨得最快的子方向和代表论文,AI 会按你的问题整理。
可以直接复制这句话问 AI
用 paperlist 查药物发现在 NeurIPS 2023–2026 的论文趋势,哪一年涨得最快?
AI 会调用的工具:get_topic_stats {"topic": "drug-discovery"}
常见问题
- 2023–2026 年四大会议一共有多少篇药物发现论文?
- 共 578 篇,按年份分别是 2023 年 79 篇、2024 年 125 篇、2025 年 163 篇、2026 年 211 篇。
- NeurIPS 2026 有多少篇药物发现论文?
- NeurIPS 2026 有 100 篇药物发现论文,上一届是 64 篇。
- ICLR 2026 有多少篇药物发现论文?
- ICLR 2026 有 37 篇药物发现论文,上一届是 48 篇。
- ICML 2026 有多少篇药物发现论文?
- ICML 2026 有 63 篇药物发现论文,上一届是 39 篇。
- CVPR 2026 有多少篇药物发现论文?
- CVPR 2026 有 11 篇药物发现论文,上一届是 12 篇。
- 哪个会议的药物发现论文最多?
- NeurIPS,2023–2026 年共 234 篇。